TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GNI Group ( (JP:2160) ) just unveiled an update.
Gyre Therapeutics, a subsidiary of GNI Group Ltd., has announced a public offering of its common stock, aiming to raise approximately $20 million. The proceeds will support the Phase 2 clinical trial of F351 in the U.S. and other corporate purposes, with a potential dilution rate of 2.83% for existing shareholders.
The most recent analyst rating on (JP:2160) stock is a Buy with a Yen3700.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on innovative drug development and therapeutic solutions. Its core subsidiary, Gyre Therapeutics, is involved in advancing clinical trials and research, particularly targeting liver fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH).
Average Trading Volume: 2,353,867
Technical Sentiment Signal: Hold
Current Market Cap: Yen124.8B
See more data about 2160 stock on TipRanks’ Stock Analysis page.